Overview
ABBV market data
Price History
ABBV price chart · 1M
- O
- 256.30
- H
- 259.54
- L
- 255.94
- C
- 257.14
- Vol
- 151,392.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $256.30
- Previous Close
- $255.03
- Day High
- $259.54
- Day Low
- $255.94
- 52 Week High
- $267.45
- 52 Week Low
- $206.27
- 7 Day Return
- +0.31%
- 30 Day Return
- +3.38%
- 90 Day Return
- +16.92%
- 1 Year Return
- +23.63%
- Daily Notional Volume
- $38.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 72.01 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.5% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 9.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $190.75 – $267.47 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $454.4B · P/B 94.44 · P/S 7.06.
Company News
10 captured
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1sZacks Investment Research ·
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPHThe Motley Fool ·
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?The Motley Fool ·
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right NowThe Motley Fool ·